CD Biosynsis offers specialized Synechococcus spp. Strain Development and Screening Services, providing an integrated high-throughput pipeline to create, isolate, and validate superior cyanobacterial variants for industrial and academic use. Synechococcus, including model strains like S. elongatus PCC 7942 and the fast-growing marine Synechococcus sp. PCC 7002, is a premier chassis for solar-driven biomanufacturing. Our services combine advanced CRISPR-mediated genome engineering with automated screening platforms to deliver strains with optimized photosynthetic efficiency, enhanced metabolic flux, and verified genetic stability across all chromosomal copies.
Developing an industrial-ready Synechococcus strain requires navigating the complexities of polyploidy and metabolic regulation. Our comprehensive program utilizes a data-driven approach, moving beyond traditional random mutagenesis toward rational strain design. We provide end-to-end support, from the initial computational mapping of metabolic pathways to the final characterization of lead clones in simulated production environments. Whether you are targeting carbon sequestration, biofuel production, or the synthesis of specialty chemicals, our platform ensures that your Synechococcus strains are genetically defined, homozygous, and fully optimized for performance in large-scale photobioreactors.
Get a QuoteSuccessful strain development in Synechococcus relies on a systematic Design-Build-Test-Learn cycle. A primary challenge in cyanobacterial engineering is achieving full chromosomal segregation in polyploid hosts. Our platform addresses this by utilizing CRISPR-Cas selective pressure to rapidly isolate homozygous mutants. We focus on identifying lead variants that exhibit high biomass productivity and target metabolite titers while maintaining robust photosynthetic health (Fv/Fm) under industrial stressors such as high light intensity and CO2 fluctuations.
Our analytical team integrates transcriptomic and metabolic profiling to characterize lead candidates. By understanding the mechanistic basis for improved performance—such as the redirection of carbon from glycogen storage to the Calvin cycle—we can iteratively refine our engineering strategies. This holistic approach ensures that the final delivered strain is not only a high producer but also maintains its metabolic traits over dozens of generations, minimizing the risk of phenotypic reversion during commercial-scale cultivation.
We provide a diversified toolkit of technologies to construct and screen high-performance Synechococcus strains tailored to your specific synthetic biology goals.
Neutral Site KI
Utilizing CRISPR-Cas9/Cas12a for precise integration into validated Neutral Sites (NS1, NS2, NS3) to ensure stable transgene expression without growth defects.
Metabolic KO
Removing competitive pathways (e.g., glycogen or PHB synthesis) to maximize the carbon flux available for target bioproduct synthesis.
Photosynthetic HTS
Utilizing microplate-based PAM fluorometry to non-invasively monitor the photosynthetic efficiency of thousands of clones under varied light regimes.
Reporter Selection
FACS-based or automated plate screening of fluorescent reporters to identify high-expressing clones or those with desired circadian rhythm profiles.
Metabolic Profiling
Quantitative analysis using GC-MS and HPLC to verify the specific titers and rates of target bioproducts (e.g., sucrose, squalene, or alcohols).
Genetic Stability
Verification of homozygous genotype and phenotype stability over 30 to 50 generations to ensure industrial readiness.
Our systematic technical pipeline ensures high-precision engineering and data-driven selection of industrial lead strains.
1. Computational Design
2. Genetic Engineering
3. HTS & Segregation
4. Stability & Scale-up
Establishing target metabolic models and designing codon-optimized cassettes. Selection of appropriate cyanobacterial promoters and Neutral Sites.
Transformation via natural competence, bacterial conjugation, or electroporation. Delivery of CRISPR machinery to initiate site-specific modification.
Evaluation of lead clones in laboratory photobioreactors under fluctuating industrial conditions. Long-term passage stability trials. Delivery of cryopreserved strains and comprehensive reports.
Rapid Segregation
Our CRISPR selective pressure techniques reduce the time required to reach homozygous status in polyploid Synechococcus by up to 70%.
Monoclonality Guaranteed
Rigorous single-cell isolation and genomic verification ensure every delivered strain is a pure, genetically defined homozygous clone.
Industrial Stress Profiling
Screening protocols simulate real-world conditions (high light, CO2 fluctuations), ensuring strains perform in photobioreactors, not just the lab.
Full OMICS Validation
Lead strains are characterized with transcriptomic and metabolic profiling to confirm pathway performance and identify further optimization nodes.
1. How do you ensure full segregation in polyploid Synechococcus?
We utilize CRISPR nucleases to actively target and eliminate wild-type genome copies. This "active selection" forces the cell to only maintain the edited genome copies, achieving homozygosity much faster than traditional antibiotic selection.
2. Can you perform strain development on marine Synechococcus isolates?
Yes, we have optimized transformation (via conjugation) and screening protocols for marine strains like Synechococcus sp. PCC 7002, which is ideal for its rapid growth and salt tolerance.
3. What is the benefit of PAM fluorometry in screening?
PAM fluorometry allows us to non-invasively monitor the photosynthetic efficiency of thousands of clones. It identifies variants that can better handle the light-saturated conditions of industrial photobioreactors.
4. Do you offer strains optimized for CO2 capture and utilization?
Yes, we can screen for and optimize the Carbon Concentrating Mechanism (CCM) components to develop strains that perform exceptionally well under high CO2 concentrations.
5. How is "genetic drift" managed during the development process?
We utilize site-specific integration at Neutral Sites and perform extensive 50-passage stability testing to ensure the genomic modifications and production phenotypes remain fixed.
6. Is the screening performed under specific light cycles?
We can simulate natural day/night cycles or constant illumination, depending on your target application, to identify clones that align with your cultivation strategy.
7. What type of reporting is provided with the final strain?
A comprehensive technical report is provided, including NGS genotyping results, growth kinetics, metabolic yield data (HPLC/GC-MS), and photosynthetic performance summaries.
8. What is the typical lead time for a custom strain development project?
Depending on the modifications and screening parameters, projects typically range from 14 to 20 weeks.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.